Dr. Reddy's Tosymra (sumatriptan nasal spray) 10mg Receives the US FDA Approval for Acute Treatment of Migraine
Shots:
- The approval is based on the clinical trial assessing Tosymra in patients with a migraine and demonstrated well tolerated and safe results
- Promius Pharma’s (subsidiary of Dr. Reddy) Tosymra (previously known as DFN-02) is a nasal spray developed using Intravail platform- targeted to treat adults with migraine with or without aura- to achieve equivalent blood level developed with the usage of 4-mg sumatriptan SC injection
- Intravail is a non-invasive drug delivery technology enabling delivery of multiple proteins- peptides and non-peptide drugs offering oral and buccal including dermal- and intranasal routes of drug administration
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
